Organisation paid for research Program year 2024 Source: CMS Open Payments

Riverchase Dermatology

Neither a doctor nor a teaching hospital

Research payments

$268,367

23 payments

Through program year 2024, Riverchase Dermatology is reported as receiving $268,367 in research payments, across 23 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $616 1
2023 Research $2,081 3
2022 Research $71,758 9
2021 Research $143,461 5
2020 Research $43,191 3
2019 Research $7,259 2

Breakdown

Who paid Research payments · program years 2019–2024
  1. Mindera Corp $135,400 7 payments
  2. Novartis Pharmaceuticals Corporation $80,891 12 payments
  3. Allergan Inc. $52,076 4 payments
Studies the money was for Research payments · program years 2019–2024
  1. Noninvasive Fat Reduction With the Coolsculpting System $35,100 2 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 2B Dose-Finding Study to Investigate the Efficacy, Safety and Tolerability of Lou064 in Adult Chronic Spontaneous Urticaria Patients Who Are Inadequately Controlled By Second Generation H1 $32,553 2 payments
  3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $19,222 1 payment
  4. Feasibility of Producing the Appearance of A Gluteal Lift Post Cryolipolysis $16,976 2 payments
  5. A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study to Determine the Efficacy and Safety of Oral Zpl389a 3 MG 10 MG 30 MG and 50 MG Capsules Administered for 16 Weeks in Subjects With Moderate to Severe Atopic Dermatitis $14,581 3 payments
  6. MATCH Study $14,366 5 payments
  7. An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Tolerability of Lou064 in Eligible Subjects With Csu Who Have Participated in Preceding Studies With Lou064 $8,930 2 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 2B Dose-Finding Study to Investigate the Efficacy, Safety and Tolerability of Lou064 in Adult Chronic Spontaneous Urticaria Patients Who Are Inadequately Controlled By Second Generation H1 Receptor Antagonists $3,462 1 payment
  9. A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $1,612 2 payments
  10. MATCH Study $554 1 payment
What the money was spent on Research payments · program years 2019–2024
  1. Patient care $14,919 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record